Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Magenta Therapeutics, Inc. MGTA
$0.65
-$0.03 (-4.04%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
41162341.00000000
-
week52high
2.24
-
week52low
0.32
-
Revenue
0
-
P/E TTM
-1
-
Beta
2.08467200
-
EPS
-1.27000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Mizuho | Buy | Buy | 18 апр 2022 г. |
| BTIG | Buy | Buy | 18 апр 2022 г. |
| B. Riley Securities | Buy | Buy | 24 янв 2022 г. |
| Goldman Sachs | Buy | Neutral | 06 янв 2022 г. |
| Goldman Sachs | Neutral | Buy | 25 авг 2022 г. |
| BTIG | Buy | Buy | 21 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Deardorf Caren | A | 19762 | 3000 | 30 ноя 2022 г. |
| Mahoney Stephen F. | A | 17264 | 3000 | 30 ноя 2022 г. |
| Beetham Thomas W. | A | 19897 | 3000 | 30 ноя 2022 г. |
| Stants Kristen | A | 20264 | 3000 | 30 ноя 2022 г. |
| GARDNER JASON | A | 292872 | 3000 | 30 ноя 2022 г. |
| VASCONCELLES MICHAEL | A | 40000 | 40000 | 15 авг 2022 г. |
| Olson Lisa | A | 100000 | 100000 | 01 авг 2022 г. |
| Nichols David Wayne | A | 75000 | 75000 | 01 авг 2022 г. |
| GARDNER JASON | A | 187500 | 187500 | 01 авг 2022 г. |
| Humphrey Jeffrey | A | 75000 | 75000 | 01 авг 2022 г. |
Новостная лента
10 Best-Performing Penny Stocks in the Health Care Sector
24/7 Wall Street
03 апр 2023 г. в 22:49
The healthcare sector has more high return generating companies than many other sectors.
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks
Zacks Investment Research
30 мар 2023 г. в 09:54
Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).
MGTA Stock: 51.66% Surge Explained
Pulse2
05 февр 2023 г. в 00:21
The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
Zacks Investment Research
21 дек 2022 г. в 09:02
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Pulse2
20 дек 2022 г. в 15:35
The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why.